Medical Care
Global Latent Tuberculosis Infection (LTBI) Testing Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 28, 25
- ID: 344187
- Pages: 125
- Figures: 116
- Views: 1
In 2024, the global market size of Latent Tuberculosis Infection (LTBI) Testing was estimated to be worth US$ 1550 million and is forecast to reach approximately US$ 2228 million by 2031 with a CAGR of 5.4% during the forecast period 2025-2031.
The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.
Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc.
Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.
The detection industry of latent tuberculosis infection (LTBI) can be subdivided into several parts: tuberculin skin test (TST), interferon release test (IGRA), etc.
Globally, there are mainly Qiagen, Oxford Immunotec, Sanofi, etc.
Diagnosing and treating latent tuberculosis infection (LTBI) is an important strategy recognized by the World Health Organization to accelerate the decline of global tuberculosis and achieve the elimination of tuberculosis. Latent tuberculosis infection (LTBI) refers to the state of continuous immune response to the stimulation of Mycobacterium tuberculosis antigen in the absence of clinical evidence of active tuberculosis (TB). The diagnosis and treatment of long-term tuberculosis is very important for tuberculosis, especially for high-risk groups. Tuberculin skin tests (TST) and interferon release tests (IGRAs) were used to diagnose LTBI.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Latent Tuberculosis Infection (LTBI) Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Latent Tuberculosis Infection (LTBI) Testing.
The Latent Tuberculosis Infection (LTBI) Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Latent Tuberculosis Infection (LTBI) Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Latent Tuberculosis Infection (LTBI) Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Qiagen
Sanofi
Oxford Immunotec
Thermo Fisher Scientific
Par Sterile
Bio-Rad Laboratories
Segment by Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
Segment by Application
Hospitals and Clinics
Diagnostic Laboratories
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Latent Tuberculosis Infection (LTBI) Testing in global and regional level.
Chapter 3: Detailed analysis of Latent Tuberculosis Infection (LTBI) Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Latent Tuberculosis Infection (LTBI) Testing revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.
Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc.
Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.
The detection industry of latent tuberculosis infection (LTBI) can be subdivided into several parts: tuberculin skin test (TST), interferon release test (IGRA), etc.
Globally, there are mainly Qiagen, Oxford Immunotec, Sanofi, etc.
Diagnosing and treating latent tuberculosis infection (LTBI) is an important strategy recognized by the World Health Organization to accelerate the decline of global tuberculosis and achieve the elimination of tuberculosis. Latent tuberculosis infection (LTBI) refers to the state of continuous immune response to the stimulation of Mycobacterium tuberculosis antigen in the absence of clinical evidence of active tuberculosis (TB). The diagnosis and treatment of long-term tuberculosis is very important for tuberculosis, especially for high-risk groups. Tuberculin skin tests (TST) and interferon release tests (IGRAs) were used to diagnose LTBI.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Latent Tuberculosis Infection (LTBI) Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Latent Tuberculosis Infection (LTBI) Testing.
The Latent Tuberculosis Infection (LTBI) Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Latent Tuberculosis Infection (LTBI) Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Latent Tuberculosis Infection (LTBI) Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Qiagen
Sanofi
Oxford Immunotec
Thermo Fisher Scientific
Par Sterile
Bio-Rad Laboratories
Segment by Type
Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
Segment by Application
Hospitals and Clinics
Diagnostic Laboratories
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Latent Tuberculosis Infection (LTBI) Testing in global and regional level.
Chapter 3: Detailed analysis of Latent Tuberculosis Infection (LTBI) Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Latent Tuberculosis Infection (LTBI) Testing revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
1 Study Coverage
1.1 Latent Tuberculosis Infection (LTBI) Testing Product Introduction
1.2 Market by Type
1.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Tuberculin Skin Test (TST)
1.2.3 Interferon Gamma Released Assay (IGRA)
1.3 Market by Application
1.3.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospitals and Clinics
1.3.3 Diagnostic Laboratories
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Size Estimates and Forecasts
2.2 Latent Tuberculosis Infection (LTBI) Testing Market Size by Region: 2024 Versus 2031
2.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Region: 2020-2025
2.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Forecast by Region (2026-2031)
2.2.3 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2031)
3.1.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2031)
3.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Tuberculin Skin Test (TST) of Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application
3.3.2 Interferon Gamma Released Assay (IGRA) of Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application
4 Global Latent Tuberculosis Infection (LTBI) Testing by Company
4.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Company (2020-2025)
4.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Latent Tuberculosis Infection (LTBI) Testing Companies around the World: Ranking by Revenue
4.3.2 Global Latent Tuberculosis Infection (LTBI) Testing Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Latent Tuberculosis Infection (LTBI) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Latent Tuberculosis Infection (LTBI) Testing Companies Headquarters & Product Type
4.4.1 Global Latent Tuberculosis Infection (LTBI) Testing Companies Headquarters
4.4.2 Date of International Companies Enter into Latent Tuberculosis Infection (LTBI) Testing Market
4.4.3 Global Latent Tuberculosis Infection (LTBI) Testing Companies Product & Service
4.4.4 Tuberculin Skin Test (TST) Revenue Market Share of Latent Tuberculosis Infection (LTBI) Testing by Company
4.4.5 Interferon Gamma Released Assay (IGRA) Revenue Market Share of Latent Tuberculosis Infection (LTBI) Testing by Company
4.5 Global Latent Tuberculosis Infection (LTBI) Testing Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Qiagen
5.1.1 Qiagen Corporation Information
5.1.2 Qiagen Description, Business Overview
5.1.3 Qiagen Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.1.4 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.1.5 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.1.6 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.1.7 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.1.8 Qiagen Recent Developments
5.2 Sanofi
5.2.1 Sanofi Corporation Information
5.2.2 Sanofi Description, Business Overview
5.2.3 Sanofi Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.2.4 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.2.5 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.2.6 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.2.7 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.2.8 Sanofi Recent Developments
5.3 Oxford Immunotec
5.3.1 Oxford Immunotec Corporation Information
5.3.2 Oxford Immunotec Description, Business Overview
5.3.3 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.3.4 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.3.5 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.3.6 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.3.7 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.3.8 Oxford Immunotec Recent Developments
5.4 Thermo Fisher Scientific
5.4.1 Thermo Fisher Scientific Corporation Information
5.4.2 Thermo Fisher Scientific Description, Business Overview
5.4.3 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.4.4 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.4.5 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.4.6 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.4.7 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.4.8 Thermo Fisher Scientific Recent Developments
5.5 Par Sterile
5.5.1 Par Sterile Corporation Information
5.5.2 Par Sterile Description, Business Overview
5.5.3 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.5.4 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.5.5 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.5.6 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.5.7 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.5.8 Par Sterile Recent Developments
5.6 Bio-Rad Laboratories
5.6.1 Bio-Rad Laboratories Corporation Information
5.6.2 Bio-Rad Laboratories Description, Business Overview
5.6.3 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.6.4 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.6.5 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.6.6 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.6.7 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.6.8 Bio-Rad Laboratories Recent Developments
6 North America
6.1 North America Latent Tuberculosis Infection (LTBI) Testing Market Size YoY Growth 2020-2031
6.2 North America Latent Tuberculosis Infection (LTBI) Testing Market Facts & Figures by Country (2020-2031)
6.3 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025)
6.4 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025)
7.4 Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025)
8 Europe
8.1 Europe Latent Tuberculosis Infection (LTBI) Testing Market Size YoY Growth 2020-2031
8.2 Europe Latent Tuberculosis Infection (LTBI) Testing Market Facts & Figures by Country (2020-2031)
8.3 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025)
8.4 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Latent Tuberculosis Infection (LTBI) Testing Market Size YoY Growth 2020-2031
9.2 Latin America Latent Tuberculosis Infection (LTBI) Testing Market Facts & Figures by Country (2020-2031)
9.3 Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025)
9.4 Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Latent Tuberculosis Infection (LTBI) Testing Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025)
10.4 Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Latent Tuberculosis Infection (LTBI) Testing Supply Chain Analysis
11.2 Latent Tuberculosis Infection (LTBI) Testing Key Raw Materials and Upstream Suppliers
11.3 Latent Tuberculosis Infection (LTBI) Testing Clients Analysis
11.4 Latent Tuberculosis Infection (LTBI) Testing Sales Channel and Sales Model Analysis
11.4.1 Latent Tuberculosis Infection (LTBI) Testing Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Latent Tuberculosis Infection (LTBI) Testing Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Latent Tuberculosis Infection (LTBI) Testing Distributors
12 Latent Tuberculosis Infection (LTBI) Testing Market Dynamics
12.1 Latent Tuberculosis Infection (LTBI) Testing Industry Trends
12.2 Latent Tuberculosis Infection (LTBI) Testing Market Drivers
12.3 Latent Tuberculosis Infection (LTBI) Testing Market Challenges
12.4 Latent Tuberculosis Infection (LTBI) Testing Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Latent Tuberculosis Infection (LTBI) Testing Product Introduction
1.2 Market by Type
1.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Tuberculin Skin Test (TST)
1.2.3 Interferon Gamma Released Assay (IGRA)
1.3 Market by Application
1.3.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospitals and Clinics
1.3.3 Diagnostic Laboratories
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Size Estimates and Forecasts
2.2 Latent Tuberculosis Infection (LTBI) Testing Market Size by Region: 2024 Versus 2031
2.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Region: 2020-2025
2.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Forecast by Region (2026-2031)
2.2.3 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2031)
3.1.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2031)
3.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Tuberculin Skin Test (TST) of Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application
3.3.2 Interferon Gamma Released Assay (IGRA) of Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application
4 Global Latent Tuberculosis Infection (LTBI) Testing by Company
4.1 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Company (2020-2025)
4.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Latent Tuberculosis Infection (LTBI) Testing Companies around the World: Ranking by Revenue
4.3.2 Global Latent Tuberculosis Infection (LTBI) Testing Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Latent Tuberculosis Infection (LTBI) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Latent Tuberculosis Infection (LTBI) Testing Companies Headquarters & Product Type
4.4.1 Global Latent Tuberculosis Infection (LTBI) Testing Companies Headquarters
4.4.2 Date of International Companies Enter into Latent Tuberculosis Infection (LTBI) Testing Market
4.4.3 Global Latent Tuberculosis Infection (LTBI) Testing Companies Product & Service
4.4.4 Tuberculin Skin Test (TST) Revenue Market Share of Latent Tuberculosis Infection (LTBI) Testing by Company
4.4.5 Interferon Gamma Released Assay (IGRA) Revenue Market Share of Latent Tuberculosis Infection (LTBI) Testing by Company
4.5 Global Latent Tuberculosis Infection (LTBI) Testing Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Qiagen
5.1.1 Qiagen Corporation Information
5.1.2 Qiagen Description, Business Overview
5.1.3 Qiagen Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.1.4 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.1.5 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.1.6 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.1.7 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.1.8 Qiagen Recent Developments
5.2 Sanofi
5.2.1 Sanofi Corporation Information
5.2.2 Sanofi Description, Business Overview
5.2.3 Sanofi Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.2.4 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.2.5 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.2.6 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.2.7 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.2.8 Sanofi Recent Developments
5.3 Oxford Immunotec
5.3.1 Oxford Immunotec Corporation Information
5.3.2 Oxford Immunotec Description, Business Overview
5.3.3 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.3.4 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.3.5 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.3.6 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.3.7 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.3.8 Oxford Immunotec Recent Developments
5.4 Thermo Fisher Scientific
5.4.1 Thermo Fisher Scientific Corporation Information
5.4.2 Thermo Fisher Scientific Description, Business Overview
5.4.3 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.4.4 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.4.5 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.4.6 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.4.7 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.4.8 Thermo Fisher Scientific Recent Developments
5.5 Par Sterile
5.5.1 Par Sterile Corporation Information
5.5.2 Par Sterile Description, Business Overview
5.5.3 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.5.4 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.5.5 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.5.6 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.5.7 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.5.8 Par Sterile Recent Developments
5.6 Bio-Rad Laboratories
5.6.1 Bio-Rad Laboratories Corporation Information
5.6.2 Bio-Rad Laboratories Description, Business Overview
5.6.3 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Products Offered
5.6.4 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2020-2025)
5.6.5 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue by Product in 2024
5.6.6 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue by Application in 2024
5.6.7 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue by Geographic Area in 2024
5.6.8 Bio-Rad Laboratories Recent Developments
6 North America
6.1 North America Latent Tuberculosis Infection (LTBI) Testing Market Size YoY Growth 2020-2031
6.2 North America Latent Tuberculosis Infection (LTBI) Testing Market Facts & Figures by Country (2020-2031)
6.3 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025)
6.4 North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025)
7.4 Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025)
8 Europe
8.1 Europe Latent Tuberculosis Infection (LTBI) Testing Market Size YoY Growth 2020-2031
8.2 Europe Latent Tuberculosis Infection (LTBI) Testing Market Facts & Figures by Country (2020-2031)
8.3 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025)
8.4 Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Latent Tuberculosis Infection (LTBI) Testing Market Size YoY Growth 2020-2031
9.2 Latin America Latent Tuberculosis Infection (LTBI) Testing Market Facts & Figures by Country (2020-2031)
9.3 Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025)
9.4 Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Latent Tuberculosis Infection (LTBI) Testing Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025)
10.4 Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Latent Tuberculosis Infection (LTBI) Testing Supply Chain Analysis
11.2 Latent Tuberculosis Infection (LTBI) Testing Key Raw Materials and Upstream Suppliers
11.3 Latent Tuberculosis Infection (LTBI) Testing Clients Analysis
11.4 Latent Tuberculosis Infection (LTBI) Testing Sales Channel and Sales Model Analysis
11.4.1 Latent Tuberculosis Infection (LTBI) Testing Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Latent Tuberculosis Infection (LTBI) Testing Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Latent Tuberculosis Infection (LTBI) Testing Distributors
12 Latent Tuberculosis Infection (LTBI) Testing Market Dynamics
12.1 Latent Tuberculosis Infection (LTBI) Testing Industry Trends
12.2 Latent Tuberculosis Infection (LTBI) Testing Market Drivers
12.3 Latent Tuberculosis Infection (LTBI) Testing Market Challenges
12.4 Latent Tuberculosis Infection (LTBI) Testing Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Latent Tuberculosis Infection (LTBI) Testing Revenue by Company (2020-2025) & (US$ Million)
Table 11. Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Latent Tuberculosis Infection (LTBI) Testing Players by Revenue (US$ Million) in 2024
Table 13. Global Latent Tuberculosis Infection (LTBI) Testing Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Latent Tuberculosis Infection (LTBI) Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Latent Tuberculosis Infection (LTBI) Testing as of 2024)
Table 15. Global Latent Tuberculosis Infection (LTBI) Testing Companies Headquarters
Table 16. Date of International Companies Enter into Latent Tuberculosis Infection (LTBI) Testing Market
Table 17. Global Latent Tuberculosis Infection (LTBI) Testing Companies Product & Service
Table 18. Global Latent Tuberculosis Infection (LTBI) Testing Mergers & Acquisitions, Expansion Plans
Table 19. Qiagen Corporation Information
Table 20. Qiagen Description and Business Overview
Table 21. Qiagen Latent Tuberculosis Infection (LTBI) Testing Product
Table 22. Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Qiagen Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 24. Qiagen Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 25. Qiagen Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 26. Qiagen Recent Developments
Table 27. Sanofi Corporation Information
Table 28. Sanofi Description and Business Overview
Table 29. Sanofi Latent Tuberculosis Infection (LTBI) Testing Product
Table 30. Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Sanofi Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 32. Sanofi Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 33. Sanofi Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 34. Sanofi Recent Developments
Table 35. Oxford Immunotec Corporation Information
Table 36. Oxford Immunotec Description and Business Overview
Table 37. Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Product
Table 38. Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Oxford Immunotec Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 40. Oxford Immunotec Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 41. Oxford Immunotec Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 42. Oxford Immunotec Recent Developments
Table 43. Thermo Fisher Scientific Corporation Information
Table 44. Thermo Fisher Scientific Description and Business Overview
Table 45. Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Product
Table 46. Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Thermo Fisher Scientific Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 48. Thermo Fisher Scientific Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 49. Thermo Fisher Scientific Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 50. Thermo Fisher Scientific Recent Developments
Table 51. Par Sterile Corporation Information
Table 52. Par Sterile Description and Business Overview
Table 53. Par Sterile Latent Tuberculosis Infection (LTBI) Testing Product
Table 54. Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Par Sterile Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 56. Par Sterile Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 57. Par Sterile Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 58. Par Sterile Recent Developments
Table 59. Bio-Rad Laboratories Corporation Information
Table 60. Bio-Rad Laboratories Description and Business Overview
Table 61. Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Product
Table 62. Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Bio-Rad Laboratories Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 64. Bio-Rad Laboratories Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 65. Bio-Rad Laboratories Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 66. Bio-Rad Laboratories Recent Developments
Table 67. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2020-2025) & (US$ Million)
Table 68. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2026-2031) & (US$ Million)
Table 69. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 70. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 71. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Region (2020-2025) & (US$ Million)
Table 72. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Region (2026-2031) & (US$ Million)
Table 73. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 74. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 75. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2020-2025) & (US$ Million)
Table 76. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2026-2031) & (US$ Million)
Table 77. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 78. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 79. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2020-2025) & (US$ Million)
Table 80. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2026-2031) & (US$ Million)
Table 81. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 82. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 83. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2020-2025) & (US$ Million)
Table 84. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2026-2031) & (US$ Million)
Table 85. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 86. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 87. Latent Tuberculosis Infection (LTBI) Testing Key Raw Materials, Industry Status and Trend
Table 88. Latent Tuberculosis Infection (LTBI) Testing Key Raw Materials and Upstream Suppliers
Table 89. Latent Tuberculosis Infection (LTBI) Testing Clients Status and Trend
Table 90. Latent Tuberculosis Infection (LTBI) Testing Typical Clients
Table 91. Latent Tuberculosis Infection (LTBI) Testing Distributors
Table 92. Latent Tuberculosis Infection (LTBI) Testing Market Trends
Table 93. Latent Tuberculosis Infection (LTBI) Testing Market Drivers
Table 94. Latent Tuberculosis Infection (LTBI) Testing Market Challenges
Table 95. Latent Tuberculosis Infection (LTBI) Testing Market Restraints
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Latent Tuberculosis Infection (LTBI) Testing Product Picture
Figure 2. Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type in 2024 & 2031
Figure 4. Tuberculin Skin Test (TST) Product Picture
Figure 5. Interferon Gamma Released Assay (IGRA) Product Picture
Figure 6. Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 7. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application in 2024 & 2031
Figure 8. Hospitals and Clinics
Figure 9. Diagnostic Laboratories
Figure 10. Others
Figure 11. Latent Tuberculosis Infection (LTBI) Testing Report Years Considered
Figure 12. Global Latent Tuberculosis Infection (LTBI) Testing Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Latent Tuberculosis Infection (LTBI) Testing Market Size (2020-2031) & (US$ Million)
Figure 14. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Market Share by Region: 2024 Versus 2031
Figure 15. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Region (2020-2031)
Figure 16. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share Forecast by Type (2020-2031)
Figure 17. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share Forecast by Application (2020-2031)
Figure 18. Tuberculin Skin Test (TST) of Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application, 2024 VS 2031
Figure 19. Interferon Gamma Released Assay (IGRA) of Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application, 2024 VS 2031
Figure 20. Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Company (2024)
Figure 21. Latent Tuberculosis Infection (LTBI) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Tuberculin Skin Test (TST) Revenue Proportion by Company in 2024
Figure 23. Interferon Gamma Released Assay (IGRA) Revenue Proportion by Company in 2024
Figure 24. North America Latent Tuberculosis Infection (LTBI) Testing Revenue 2020-2031 (US$ Million)
Figure 25. North America Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2025)
Figure 26. North America Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2025)
Figure 27. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue 2020-2031 (US$ Million)
Figure 28. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Region (2020-2031)
Figure 29. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2025)
Figure 30. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2025)
Figure 31. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 32. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Country (2020-2031)
Figure 33. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2025)
Figure 34. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2025)
Figure 35. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 36. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Country (2020-2031)
Figure 37. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2025)
Figure 38. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2025)
Figure 39. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 40. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Country (2020-2031)
Figure 41. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2025)
Figure 42. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2025)
Figure 43. Latent Tuberculosis Infection (LTBI) Testing Supply Chain (Upstream and Downstream Market)
Figure 44. Global Production Market Share of Latent Tuberculosis Infection (LTBI) Testing Raw Materials by Region in 2024
Figure 45. Latent Tuberculosis Infection (LTBI) Testing Distribution Channels
Figure 46. Global Latent Tuberculosis Infection (LTBI) Testing Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 47. Global Latent Tuberculosis Infection (LTBI) Testing Percentage 2020-2031: Online Sales VS Offline Sales
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Table 1. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Latent Tuberculosis Infection (LTBI) Testing Revenue by Company (2020-2025) & (US$ Million)
Table 11. Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Latent Tuberculosis Infection (LTBI) Testing Players by Revenue (US$ Million) in 2024
Table 13. Global Latent Tuberculosis Infection (LTBI) Testing Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Latent Tuberculosis Infection (LTBI) Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Latent Tuberculosis Infection (LTBI) Testing as of 2024)
Table 15. Global Latent Tuberculosis Infection (LTBI) Testing Companies Headquarters
Table 16. Date of International Companies Enter into Latent Tuberculosis Infection (LTBI) Testing Market
Table 17. Global Latent Tuberculosis Infection (LTBI) Testing Companies Product & Service
Table 18. Global Latent Tuberculosis Infection (LTBI) Testing Mergers & Acquisitions, Expansion Plans
Table 19. Qiagen Corporation Information
Table 20. Qiagen Description and Business Overview
Table 21. Qiagen Latent Tuberculosis Infection (LTBI) Testing Product
Table 22. Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Qiagen Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 24. Qiagen Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 25. Qiagen Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 26. Qiagen Recent Developments
Table 27. Sanofi Corporation Information
Table 28. Sanofi Description and Business Overview
Table 29. Sanofi Latent Tuberculosis Infection (LTBI) Testing Product
Table 30. Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Sanofi Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 32. Sanofi Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 33. Sanofi Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 34. Sanofi Recent Developments
Table 35. Oxford Immunotec Corporation Information
Table 36. Oxford Immunotec Description and Business Overview
Table 37. Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Product
Table 38. Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Oxford Immunotec Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 40. Oxford Immunotec Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 41. Oxford Immunotec Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 42. Oxford Immunotec Recent Developments
Table 43. Thermo Fisher Scientific Corporation Information
Table 44. Thermo Fisher Scientific Description and Business Overview
Table 45. Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Product
Table 46. Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Thermo Fisher Scientific Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 48. Thermo Fisher Scientific Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 49. Thermo Fisher Scientific Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 50. Thermo Fisher Scientific Recent Developments
Table 51. Par Sterile Corporation Information
Table 52. Par Sterile Description and Business Overview
Table 53. Par Sterile Latent Tuberculosis Infection (LTBI) Testing Product
Table 54. Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Par Sterile Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 56. Par Sterile Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 57. Par Sterile Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 58. Par Sterile Recent Developments
Table 59. Bio-Rad Laboratories Corporation Information
Table 60. Bio-Rad Laboratories Description and Business Overview
Table 61. Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Product
Table 62. Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Bio-Rad Laboratories Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Product in 2024
Table 64. Bio-Rad Laboratories Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Application in 2024
Table 65. Bio-Rad Laboratories Revenue Proportion of Latent Tuberculosis Infection (LTBI) Testing by Geographic Area in 2024
Table 66. Bio-Rad Laboratories Recent Developments
Table 67. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2020-2025) & (US$ Million)
Table 68. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2026-2031) & (US$ Million)
Table 69. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 70. North America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 71. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Region (2020-2025) & (US$ Million)
Table 72. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Region (2026-2031) & (US$ Million)
Table 73. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 74. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 75. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2020-2025) & (US$ Million)
Table 76. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2026-2031) & (US$ Million)
Table 77. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 78. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 79. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2020-2025) & (US$ Million)
Table 80. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2026-2031) & (US$ Million)
Table 81. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 82. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 83. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2020-2025) & (US$ Million)
Table 84. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Country (2026-2031) & (US$ Million)
Table 85. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Type (2020-2025) & (US$ Million)
Table 86. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue by Application (2020-2025) & (US$ Million)
Table 87. Latent Tuberculosis Infection (LTBI) Testing Key Raw Materials, Industry Status and Trend
Table 88. Latent Tuberculosis Infection (LTBI) Testing Key Raw Materials and Upstream Suppliers
Table 89. Latent Tuberculosis Infection (LTBI) Testing Clients Status and Trend
Table 90. Latent Tuberculosis Infection (LTBI) Testing Typical Clients
Table 91. Latent Tuberculosis Infection (LTBI) Testing Distributors
Table 92. Latent Tuberculosis Infection (LTBI) Testing Market Trends
Table 93. Latent Tuberculosis Infection (LTBI) Testing Market Drivers
Table 94. Latent Tuberculosis Infection (LTBI) Testing Market Challenges
Table 95. Latent Tuberculosis Infection (LTBI) Testing Market Restraints
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Latent Tuberculosis Infection (LTBI) Testing Product Picture
Figure 2. Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type in 2024 & 2031
Figure 4. Tuberculin Skin Test (TST) Product Picture
Figure 5. Interferon Gamma Released Assay (IGRA) Product Picture
Figure 6. Global Latent Tuberculosis Infection (LTBI) Testing Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 7. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application in 2024 & 2031
Figure 8. Hospitals and Clinics
Figure 9. Diagnostic Laboratories
Figure 10. Others
Figure 11. Latent Tuberculosis Infection (LTBI) Testing Report Years Considered
Figure 12. Global Latent Tuberculosis Infection (LTBI) Testing Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Latent Tuberculosis Infection (LTBI) Testing Market Size (2020-2031) & (US$ Million)
Figure 14. Global Latent Tuberculosis Infection (LTBI) Testing Market Size Market Share by Region: 2024 Versus 2031
Figure 15. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Region (2020-2031)
Figure 16. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share Forecast by Type (2020-2031)
Figure 17. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share Forecast by Application (2020-2031)
Figure 18. Tuberculin Skin Test (TST) of Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application, 2024 VS 2031
Figure 19. Interferon Gamma Released Assay (IGRA) of Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application, 2024 VS 2031
Figure 20. Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Company (2024)
Figure 21. Latent Tuberculosis Infection (LTBI) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Tuberculin Skin Test (TST) Revenue Proportion by Company in 2024
Figure 23. Interferon Gamma Released Assay (IGRA) Revenue Proportion by Company in 2024
Figure 24. North America Latent Tuberculosis Infection (LTBI) Testing Revenue 2020-2031 (US$ Million)
Figure 25. North America Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2025)
Figure 26. North America Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2025)
Figure 27. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue 2020-2031 (US$ Million)
Figure 28. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Region (2020-2031)
Figure 29. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2025)
Figure 30. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2025)
Figure 31. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 32. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Country (2020-2031)
Figure 33. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2025)
Figure 34. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2025)
Figure 35. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 36. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Country (2020-2031)
Figure 37. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2025)
Figure 38. Latin America Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2025)
Figure 39. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue Growth Rate 2020-2031 (US$ Million)
Figure 40. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Country (2020-2031)
Figure 41. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Type (2020-2025)
Figure 42. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue Market Share by Application (2020-2025)
Figure 43. Latent Tuberculosis Infection (LTBI) Testing Supply Chain (Upstream and Downstream Market)
Figure 44. Global Production Market Share of Latent Tuberculosis Infection (LTBI) Testing Raw Materials by Region in 2024
Figure 45. Latent Tuberculosis Infection (LTBI) Testing Distribution Channels
Figure 46. Global Latent Tuberculosis Infection (LTBI) Testing Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 47. Global Latent Tuberculosis Infection (LTBI) Testing Percentage 2020-2031: Online Sales VS Offline Sales
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232